Holen Sie sich die Stockscreener-App
8.24
1.44%
-0.12
Vorhandelsmarkt:
8.25
0.010
+0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.36
Offen:
$8.39
24-Stunden-Volumen:
1.11M
Relative Volume:
0.54
Marktkapitalisierung:
$1.07B
Einnahmen:
$745.97M
Nettoeinkommen (Verlust:
$-99.21M
KGV:
-10.66
EPS:
-0.7729
Netto-Cashflow:
$-5.09M
1W Leistung:
-8.04%
1M Leistung:
-5.07%
6M Leistung:
-20.31%
1J Leistung:
+5.10%
1-Tages-Spanne:
$8.22
$8.43
1-Wochen-Bereich:
$8.175
$8.99
52-Wochen-Spanne:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
8.24 | 1.09B | 745.97M | -99.21M | -5.09M | -0.7729 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-29 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know - Yahoo Finance
NEOGENOMICS (NEO) 13G/A: Greenhouse reports 9,215,903 shares (7.1%) - Stock Titan
Oncology diagnostics group NeoGenomics meets investors at May, June conferences - Stock Titan
NeoGenomics to Participate in Upcoming Investor Conferences - The Joplin Globe
Laser Focus WorldNeoGenomics to Participate in Upcoming Investor Conferences - FinancialContent
(NEO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Millennium group reports 2.22M NEO shares (1.7%) — Joint filing (NEO) - Stock Titan
NeoGenomics (NEO) EVP adds shares via RSU vesting while covering taxes - Stock Titan
NeoGenomics (NEO) COO exercises RSUs, withholds shares for taxes and holds 164,032 shares - Stock Titan
TradingKey - TradingKey
Is NeoGenomics’ Higher 2026 Revenue Outlook And Narrower Loss Profile Altering The Investment Case For NEO? - Sahm
NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
NeoGenomics Inc. (NEO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NEO PE Ratio & Valuation, Is NEO Overvalued - Intellectia AI
First Light, Mathew Arens report 10.8% stakes in Neogenomics (NEO) - Stock Titan
NeoGenomics (NEO) Q1 2026 Earnings Transcript - AOL.com
NEO SEC FilingsNeogenomics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
NeoGenomics shares jump on earnings and analyst upgrades - MSN
NeoGenomics (NEO) CAO exercises RSUs, surrenders shares for taxes - Stock Titan
NeoGenomics (NEO) EVP updates equity awards, reports tax-withholding share move - Stock Titan
NeoGenomics (NEO) COO exercises RSUs, shares withheld for tax - Stock Titan
MSN Money - MSN
5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call - The Globe and Mail
NeoGenomics slides more than 5% despite fourth-quarter earnings beat - MSN
Liquidity Mapping Around (NEO) Price Events - Stock Traders Daily
NeoGenomics (NEO) Is Up 13.9% After Strong Q1 Revenue And New Epic Aura Integration - simplywall.st
NeoGenomics (NEO) Q1 2025 Earnings Transcript - AOL.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opus Genetics (IRD), NeoGenomics (NEO) and Teladoc (TDOC) - The Globe and Mail
A Look At NeoGenomics (NEO) Valuation After Q1 2026 Results And Epic Aura Oncology Integration - Yahoo Finance
BTIG Maintains NeoGenomics(NEO.US) With Hold Rating - Moomoo
Vanguard holds 6.61M NeoGenomics shares (NEO) — 5.09% stake - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
NeoGenomics reports Q1 revenue increase - Gulfshore Business
NeoGenomics Reports First Quarter 2026 Financial Results - HarianBasis.co
Leerink Partners upgrades NeoGenomics (NEO) - MSN
NeoGenomics Earnings Call Highlights NGS-Led Growth - TipRanks
TD Cowen Issues Positive Forecast for NeoGenomics (NASDAQ:NEO) Stock Price - MarketBeat
Vanguard Portfolio Management holds 5.91% of NeoGenomics (NEO) common stock - Stock Titan
Leerink upgrades Neogenomics stock rating on oncology growth outlook By Investing.com - Investing.com Nigeria
NeoGenomics (NASDAQ:NEO) Shares Gap Up Following Analyst Upgrade - MarketBeat
NeoGenomics (NASDAQ:NEO) Upgraded by Leerink Partners to Outperform Rating - MarketBeat
Leerink upgrades NeoGenomics to Outperform, raises target to $25 - TipRanks
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2026 Earnings Call Transcript - Insider Monkey
Leerink Upgrades NeoGenomics to Outperform From Market Perform, Adjusts Price Target to $25 From $12 - marketscreener.com
Needham reiterates Neogenomics stock Buy rating on strong Q1 beat - Investing.com UK
Needham reiterates Neogenomics stock Buy rating on strong Q1 beat By Investing.com - Investing.com South Africa
NeoGenomics Shares Jump on Earnings and Analyst Upgrades - Yahoo Finance
Leerink upgrades Neogenomics stock rating on oncology growth outlook - Investing.com
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):